Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer
Author:
Laura L. Michel,Philipp Ziegler,Philipp Kreis,Andreas D. Hartkopf,Markus Wallwiener,Lothar Häberle,Nelson John,Hans-Christian Kolberg,Peyman Hadji,Hans Tesch,Johannes Ettl,Diana Lüftner,Volkmar Müller,Erik Belleville,Pauline Wimberger et al.
Publication:
European Journal of Cancer
© 2025 The Authors. Published by Elsevier Ltd.